Noxopharm (ASX:NOX) Change In Payables And Accrued Expense : A$0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Noxopharm Change In Payables And Accrued Expense?

Noxopharm's Change In Payables And Accrued Expense for the quarter that ended in Dec. 2023 was A$0.00 Mil. It means Noxopharm's Accounts Payable & Accrued Expense stayed the same from Jun. 2023 to Dec. 2023 .

Noxopharm's Change In Payables And Accrued Expense for the fiscal year that ended in Jun. 2023 was A$0.00 Mil. It means Noxopharm's Accounts Payable & Accrued Expense stayed the same from Jun. 2022 to Jun. 2023 .

Noxopharm Change In Payables And Accrued Expense Historical Data

The historical data trend for Noxopharm's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Noxopharm Change In Payables And Accrued Expense Chart

Noxopharm Annual Data

Trend

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

Noxopharm Semi-Annual Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Change In Payables And Accrued Expense	Get a 7-Day Free Trial										-	-	-	-	-

Noxopharm Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.00 Mil.

Noxopharm Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Noxopharm's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Noxopharm (ASX:NOX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Noxopharm Ltd (ASX:NOX) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

NOXOF:USA

Address

60 Linksley Ave, Glenhaven, NSW, AUS, 2156

Website

https://www.noxopharm.com

Noxopharm Ltd is an Australian clinical-stage drug development company focused on treating cancer with Veyonda. It is engaged in the development in the field of both oncology and non-oncology in the pan-pacific region.

Noxopharm (ASX:NOX) Headlines

No Headlines